CTLA-4 Control over Foxp3 + Regulatory T Cell Function
The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Naturally occurring Foxp3+CD4+ regulatory T cells (Tregs) are essential for maintaining immunological self-tolerance and immune homeostasis. Here, we show that a specific deficiency of cytotoxic T lymphocyte antigen 4 (CTLA-4) in Tregs results in spontaneous development of systemic lymphoproliferation, fatal T cell-mediated autoimmune disease, and hyperproduction of immunoglobulin E in mice, and it also produces potent tumor immunity. Treg-specific CTLA-4 deficiency impairs in vivo and in vitro suppressive function of Tregs-in particular, Treg-mediated down-regulation of CD80 and CD86 expression on dendritic cells. Thus, natural Tregs may critically require CTLA-4 to suppress immune responses by affecting the potency of antigen-presenting cells to activate other T cells.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The central role that CTLA-4 plays in immunological tolerance is exemplified by experiments in mice that lack the CTLA-4 gene globally or specifically in the Forkhead box P3 (FoxP3)+ Treg compartment. These animals develop lymphoproliferative disorders and die at a young age (25, 26).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [25]
In the citing paper
“Indeed, this process is an important mechanism by which Tregs mediate immune suppression on bystander cells (25).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [25]
In the citing paper
“Of note, although CTLA4 blockade was shown to cause selective depletion of intratumoral Tregs through antibody-dependent cell-mediated cytotoxicity (ADCC) in murine models and ex vivo experiments on human tumor samples (24)(25)(26),”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [24]
In the citing paper
“The CTLA-4 regulatory effects mainly temper the activation of CD4+ helper T cells while boosting regulatory T cells (Tregs) (Doyle et al., 2001; Wing et al., 2008), leading to a pro-tumor immunosuppressive phenotype.”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Wing et al., 2008
Citations
Cites
Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls
The Wellcome Trust Case Control Consortium, Management Committee, Burton, P. R., Clayton, D. G., Cardon, L. R., Craddock, N., Deloukas, P., Duncanson, A., Kwiatkowski, D. P., McCarthy, M. I., et al. (2007) · Nature · doi:10.1038/nature05911 · Cited by 9,442
Control of Regulatory T Cell Development by the Transcription Factor Foxp3
Hori, S., Nomura, T., & Sakaguchi, S. (2003) · Science · doi:10.1126/science.1079490 · Cited by 8,187
Self-citationRegulatory T Cells and Immune Tolerance
Sakaguchi, S., Yamaguchi, T., Nomura, T., & Ono, M. (2008) · Cell · doi:10.1016/j.cell.2008.05.009 · Cited by 5,325
Self-citationEnhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955
Tivol, E. A., Borriello, F., Schweitzer, A. N., Lynch, W. P., Bluestone, J. A., & Sharpe, A. H. (1995) · Immunity · doi:10.1016/1074-7613(95)90125-6 · Cited by 2,914
Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Griesser, H., & Mak, T. W. (1995) · Science · doi:10.1126/science.270.5238.985 · Cited by 2,766
Takahashi, T., Tagami, T., Yamazaki, S., Uede, T., Shimizu, J., Sakaguchi, N., Mak, T. W., & Sakaguchi, S. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.303 · Cited by 2,233
Self-citationRead, S., Malmström, V., & Powrie, F. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.295 · Cited by 2,205
Salomon, B., Lenschow, D. J., Rhee, L., Ashourian, N., Singh, B., Sharpe, A., & Bluestone, J. A. (2000) · Immunity · doi:10.1016/s1074-7613(00)80195-8 · Cited by 2,081
Phan, G. Q., Yang, J. C., Sherry, R. M., Hwu, P., Topalian, S. L., Schwartzentruber, D. J., Restifo, N. P., Haworth, L. R., Seipp, C. A., Freezer, L. J., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1533209100 · Cited by 1,575
Research works printed but not linked: 1
- 10.1002/1521-4141(200006)30:6<1538::aid-immu1538>3.0.co;2-x · doi:10.1002/1521-4141(200006)30:6<1538::aid-immu1538>3.0.co;2-x
Cited by
Items 201–300 of 1,010
Tumour-infiltrating lymphocytes in melanoma prognosis and cancer immunotherapy
Lee, N., Zakka, L. R., Mihm, M. C., & Schatton, T. (2016) · Pathology · doi:10.1016/j.pathol.2015.12.006 · Cited by 250
Duarte, J. H., Zelenay, S., Bergman, M., Martins, A. C., & Demengeot, J. (2009) · European Journal of Immunology · doi:10.1002/eji.200839196 · Cited by 250
Neuropilin 1 deficiency on CD4+Foxp3+ regulatory T cells impairs mouse melanoma growth
Hansen, W., Hutzler, M., Abel, S., Alter, C., Stockmann, C., Kliche, S., Albert, J., Sparwasser, T., Sakaguchi, S., Westendorf, A. M., et al. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20111497 · Cited by 250
“…John Hopkins University, Baltimore, MD; Gu et al., 2003), CD4cre mice (provided by W. Müller, University of Manchester, Manchester, UK), FIC mice (Wing et al., 2008), DEREG mice (Lahl et al., 2007), C57/BL6 mice (Harlan), and MT/ret mice (provided by M. Kato, Chubu University, Aichi, Japan) were…”
BackgroundInfluentialSelf-citationA reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy
Du, X., Tang, F., Liu, M., Su, J., Zhang, Y., Wu, W., Devenport, M., Lazarski, C. A., Zhang, P., Wang, X., et al. (2018) · Cell Research · doi:10.1038/s41422-018-0011-0 · Cited by 249
Cardiotoxicity of immune checkpoint inhibitors
Varricchi, G., Galdiero, M. R., Marone, G., Criscuolo, G., Triassi, M., Bonaduce, D., Marone, G., & Tocchetti, C. G. (2017) · ESMO Open · doi:10.1136/esmoopen-2017-000247 · Cited by 246
The Journey from Discoveries in Fundamental Immunology to Cancer Immunotherapy
Miller, J. F. A. P., & Sadelain, M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.007 · Cited by 245
Anti-programmed cell death protein-1/ligand-1 therapy in different cancers
Homet Moreno, B., & Ribas, A. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.124 · Cited by 245
“Antibodies that block CTLA-4 enhance immune responses by activating effector T cells, but probably also by interacting with other immune cells such as regulatory T cells (Tregs), which exhibit immunosuppressive properties (Lenschow et al, 1996; Wing et al, 2008).”
BackgroundAnti–CTLA-4 Antibody Therapy: Immune Monitoring During Clinical Development of a Novel Immunotherapy
Callahan, M. K., Wolchok, J. D., & Allison, J. P. (2010) · Seminars in Oncology · doi:10.1053/j.seminoncol.2010.09.001 · Cited by 245
Inhibitory Receptors Beyond T Cell Exhaustion
Fuertes Marraco, S. A., Neubert, N. J., Verdeil, G., & Speiser, D. E. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00310 · Cited by 244
“In addition to its important constitutive expression and function in Treg cells (97), CTLA-4 is up-regulated following T cell activation (98), and is involved in late stages of T cell priming and systemic activation of T cell responses [reviewed in Ref.”
BackgroundMolecular and Cellular Functions of CTLA-4
Van Coillie, S., Wiernicki, B., & Xu, J. (2020) · Advances in Experimental Medicine and Biology · doi:10.1007/978-981-15-3266-5_2 · Cited by 243
Regulatory T Cells: the Many Faces of Foxp3
Georgiev, P., Charbonnier, L.-M., & Chatila, T. A. (2019) · Journal of Clinical Immunology · doi:10.1007/s10875-019-00684-7 · Cited by 241
Immune checkpoint blockade in hepatocellular carcinoma: Current progress and future directions
Hato, T., Goyal, L., Greten, T. F., Duda, D. G., & Zhu, A. X. (2014) · Hepatology · doi:10.1002/hep.27246 · Cited by 241
“Treg-specific knockout or blockade of CTLA-4 inhibits their ability to regulate both autoimmunity and anticancer immunity [39, 40].”
BackgroundSchmidl, C., Klug, M., Boeld, T. J., Andreesen, R., Hoffmann, P., Edinger, M., & Rehli, M. (2009) · Genome Research · doi:10.1101/gr.091470.109 · Cited by 240
“…were found upstream of IKZF2, encoding a regulator of lymphocyte development (Dovat et al. 2005), and CTLA4, encoding a molecule that is constitutively expressed on Treg cells and that suppresses immune responses by affecting the activating potency of antigen-presenting cells (Wing et al. 2008).”
BackgroundCurrent understanding of CTLA-4: from mechanism to autoimmune diseases
Hossen, M. M., Ma, Y., Yin, Z., Xia, Y., Du, J., Huang, J. Y., Huang, J. J., Zou, L., Ye, Z., & Huang, Z. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1198365 · Cited by 238
Dynamic Treg interactions with intratumoral APCs promote local CTL dysfunction
Bauer, C. A., Kim, E. Y., Marangoni, F., Carrizosa, E., Claudio, N. M., & Mempel, T. R. (2014) · Journal of Clinical Investigation · doi:10.1172/jci66375 · Cited by 238
“Here we found that rapid downregulation of CD80 and CD86 on DCs (27, 28) occurred most effectively when Tregs encountered their cognate Ag on DCs in vitro.”
Immune checkpoint inhibitor–associated myocarditis: manifestations and mechanisms
Moslehi, J., Lichtman, A. H., Sharpe, A. H., Galluzzi, L., & Kitsis, R. N. (2021) · Journal of Clinical Investigation · doi:10.1172/jci145186 · Cited by 237
“Tregs, most of which are CD4+CD25+ and express the FOXP3 transcription factor, arise primarily in the thymus but also in peripheral tissues (48, 49).”
BackgroundInfluentialCancer Immunotherapy: A Future Paradigm Shift in the Treatment of Non–Small Cell Lung Cancer
Anagnostou, V. K., & Brahmer, J. R. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1187 · Cited by 237
VISTA is a novel broad-spectrum negative checkpoint regulator for cancer immunotherapy
Lines, J. L., Sempere, L. F., Broughton, T., Wang, L., & Noelle, R. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0072 · Cited by 236
Kitoh, A., Ono, M., Naoe, Y., Ohkura, N., Yamaguchi, T., Yaguchi, H., Kitabayashi, I., Tsukada, T., Nomura, T., Miyachi, Y., et al. (2009) · Immunity · doi:10.1016/j.immuni.2009.09.003 · Cited by 236
“Foxp3-Ires-Cre 618 Immunity 31, 609–620, October 16, 2009 ª2009 Elsevier Inc. (FIC), Runx1F, Runx3F, and CbfbF mouse strains were described previously (Naoe et al., 2007; Taniuchi et al., 2002; Wing et al., 2008).”
BackgroundMethodSelf-citationYamaguchi, T., Wing, J. B., & Sakaguchi, S. (2011) · Seminars in Immunology · doi:10.1016/j.smim.2011.10.002 · Cited by 236
“In addition, the expression of CD80 and CD86 on APCs is downregulated by co-culture with activated Tregs in a CTLA-4 dependent manner [31,35,41,42].”
BackgroundSelf-citationDejean, A. S., Beisner, D. R., Ch'en, I. L., Kerdiles, Y. M., Babour, A., Arden, K. C., Castrillon, D. H., DePinho, R. A., & Hedrick, S. M. (2009) · Nature Immunology · doi:10.1038/ni.1729 · Cited by 235
Immunotherapy of Hepatocellular Carcinoma: Facts and Hopes
Iñarrairaegui, M., Melero, I., & Sangro, B. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0289 · Cited by 235
“CTLA-4 is also constitutively expressed on Tregs, where it is required for effector T-cell inhibition through various mechanisms (5).”
BackgroundOo, Y. H., Weston, C. J., Lalor, P. F., Curbishley, S. M., Withers, D. R., Reynolds, G. M., Shetty, S., Harki, J., Shaw, J. C., Eksteen, B., et al. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0901216 · Cited by 232
Induction of autoimmune disease by deletion of CTLA-4 in mice in adulthood
Klocke, K., Sakaguchi, S., Holmdahl, R., & Wing, K. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1603892113 · Cited by 232
“CTLA-4–deficient Treg cells, in particular in vivo activated ones, can clearly use alternative mechanisms to suppress immune responses as they can suppress anti-CD3 Ab-induced T-cell proliferation to the same degree as WT Treg cells (15, 18).”
BackgroundInfluentialSelf-citationThe Treg/Th17 Cell Balance: A New Paradigm for Autoimmunity
Eisenstein, E. M., & Williams, C. B. (2009) · Pediatric Research · doi:10.1203/pdr.0b013e31819e76c7 · Cited by 231
Selby, M. J., Engelhardt, J. J., Johnston, R. J., Lu, L.-S., Han, M., Thudium, K., Yao, D., Quigley, M., Valle, J., Wang, C., et al. (2016) · PLOS ONE · doi:10.1371/journal.pone.0161779 · Cited by 231
Pierson, W., Cauwe, B., Policheni, A., Schlenner, S. M., Franckaert, D., Berges, J., Humblet-Baron, S., Schönefeldt, S., Herold, M. J., Hildeman, D., et al. (2013) · Nature Immunology · doi:10.1038/ni.2649 · Cited by 231
Regulatory T cells in autoimmune neuroinflammation
Kleinewietfeld, M., & Hafler, D. A. (2014) · Immunological Reviews · doi:10.1111/imr.12169 · Cited by 230
“Tregs can modulate DC function by CTLA-4 ligation of CD80 and CD86, thereby inhibiting DC costimulation of effector T cells (59).”
BackgroundGeneration and Function of Induced Regulatory T Cells
Schmitt, E. G., & Williams, C. B. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00152 · Cited by 229
“A recent study demonstrated that in vitro-derived iTreg cells cotransferred with naïve T cells into Rag−/− hosts were not effective in preventing colitis and many of the iTreg cells had decreased Foxp3, CTLA-4, and CD25 expression (Ohkura et al., 2012).”
BackgroundInfluentialKaufmann, D. E., & Walker, B. D. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0803771 · Cited by 229
“CTLA-4 is also constitutively expressed on regulatory T cells and plays a crucial role in their regulation and function ( 15 , 16).”
BackgroundCAR T cells for infection, autoimmunity and allotransplantation
Maldini, C. R., Ellis, G. I., & Riley, J. L. (2018) · Nature Reviews Immunology · doi:10.1038/s41577-018-0042-2 · Cited by 229
Targeting regulatory T cells in tumors
Liu, C., Workman, C. J., & Vignali, D. A. A. (2016) · The FEBS Journal · doi:10.1111/febs.13656 · Cited by 228
Enhanced suppressor function of TIM‐3+FoxP3+ regulatory T cells
Gautron, A., Dominguez‐Villar, M., de Marcken, M., & Hafler, D. A. (2014) · European Journal of Immunology · doi:10.1002/eji.201344392 · Cited by 228
“Statistical significance determined by a two-tailed standard t-test. expression of CTLA-4, LAG-3, and PD-1 on TIM-3+ Treg cells, cell surface molecules described as important in human and murine Treg-cell-suppressive function [24–26].”
BackgroundInfluentialTargeting co-stimulatory molecules in autoimmune disease
Edner, N. M., Carlesso, G., Rush, J. S., & Walker, L. S. K. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0081-9 · Cited by 228
Carosella, E. D., Ploussard, G., LeMaoult, J., & Desgrandchamps, F. (2015) · European Urology · doi:10.1016/j.eururo.2015.02.032 · Cited by 227
“B M S9 3 6 5 5 9 [3 5 ] 1 0 .”
BackgroundHan, Y., Chen, Z., Yang, Y., Jiang, Z., Gu, Y., Liu, Y., Lin, C., Pan, Z., Yu, Y., Jiang, M., et al. (2014) · Hepatology · doi:10.1002/hep.26694 · Cited by 226
“Unexpectedly, CD141DCs expressed high levels of CTLA-4 and PD-1, two key inhibitory receptors, mainly expressed on Tregs and activated T cells, that critically affect peripheral T-cell function.36 Many studies have demonstrated that CTLA-4 is required of Tregs to suppress immune responses by affecting APCs.37,38 Ipili…”
BackgroundA2aR antagonists: Next generation checkpoint blockade for cancer immunotherapy
Leone, R. D., Lo, Y.-C., & Powell, J. D. (2015) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2015.03.008 · Cited by 225
“CTLA-4 is also strongly expressed on regulatory T cells and enhances immunosuppression through enhancing Treg activity and proliferation [12].”
BackgroundThe yin and yang of co-inhibitory receptors: toward anti-tumor immunity without autoimmunity
Schnell, A., Bod, L., Madi, A., & Kuchroo, V. K. (2020) · Cell Research · doi:10.1038/s41422-020-0277-x · Cited by 224
“In cancer, CTLA-4 is expressed on activated CD4 and CD8 T cells and on Treg cells.(9,150,151) CTLA-4 can also be expressed by tumor cells themselves.”
BackgroundInfluentialIpilimumab: controversies in its development, utility and autoimmune adverse events
Weber, J. (2009) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-008-0653-8 · Cited by 224
“It is particularly found at high levels on T regulatory cells [31].”
BackgroundBour‐Jordan, H., & Bluestone, J. A. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00775.x · Cited by 223
“While the mechanisms underlying the diminution in the expression of B7 molecules on DCs after direct interaction with Tregs are unknown, they were shown to result from down-modulation of B7 molecules rather than masking by soluble CTLA-4 (211).”
BackgroundResultInfluentialCurrent Status and Future Directions
Ito, F., & Chang, A. E. (2013) · Cited by 223
Chemokines beyond chemo-attraction: CXCL10 and its significant role in cancer and autoimmunity
Karin, N., & Razon, H. (2018) · Cytokine · doi:10.1016/j.cyto.2018.02.012 · Cited by 222
“Signaling via the CTLA4/B7-1 and B7-2 pathways restrains effector T cell responses [67].”
BackgroundBooth, N. J., McQuaid, A. J., Sobande, T., Kissane, S., Agius, E., Jackson, S. E., Salmon, M., Falciani, F., Yong, K., Rustin, M. H., et al. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903781 · Cited by 220
Cutting Edge: Mechanisms of IL-2–Dependent Maintenance of Functional Regulatory T Cells
Barron, L., Dooms, H., Hoyer, K. K., Kuswanto, W., Hofmann, J., O’Gorman, W. E., & Abbas, A. K. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903940 · Cited by 219
“Because multiple pathways may be essential but not sufficient for fully functional Tregs (17, 19, 20, 23), the seemingly pleiotropic effects of IL-2 could boost immune regulation in a range of situations.”
BackgroundInfluentialKennedy, A., Waters, E., Rowshanravan, B., Hinze, C., Williams, C., Janman, D., Fox, T. A., Booth, C., Pesenacker, A. M., Halliday, N., et al. (2022) · Nature Immunology · doi:10.1038/s41590-022-01289-w · Cited by 218
Treg cells in health and autoimmune diseases: New insights from single cell analysis
Scheinecker, C., Göschl, L., & Bonelli, M. (2020) · Journal of Autoimmunity · doi:10.1016/j.jaut.2019.102376 · Cited by 218
Kwan, W.-H., van der Touw, W., Paz-Artal, E., Li, M. O., & Heeger, P. S. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20121525 · Cited by 215
“2, D and E), one molecule through which nT reg cells are known to me diate their suppressive function (Wing et al., 2008).”
BackgroundInfluentialMuroyama, Y., Nirschl, T. R., Kochel, C. M., Lopez-Bujanda, Z., Theodros, D., Mao, W., Carrera-Haro, M. A., Ghasemzadeh, A., Marciscano, A. E., Velarde, E., et al. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0040 · Cited by 215
“S12). www.aacrjournals.org Cancer Immunol Res; 5(11) November 2017 999 Cancer Immunol Res; 5(11) November 2017 Cancer Immunology Research1000 TIL-Tregs retain suppressive function after RT Based on their increased expression of CTLA-4 (28) and Helios (29–31), we queried whether TIL-Tregs demonstrated increased suppres…”
InfluentialCAR T‐Cell‐Based gene therapy for cancers: new perspectives, challenges, and clinical developments
Jogalekar, M. P., Rajendran, R. L., Khan, F., Dmello, C., Gangadaran, P., & Ahn, B.-C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.925985 · Cited by 214
Treg cells in autoimmunity: from identification to Treg-based therapies
Göschl, L., Scheinecker, C., & Bonelli, M. (2019) · Seminars in Immunopathology · doi:10.1007/s00281-019-00741-8 · Cited by 214
TREG-cell therapies for autoimmune rheumatic diseases
Miyara, M., Ito, Y., & Sakaguchi, S. (2014) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2014.105 · Cited by 214
Self-citationCurran, M. A., Kim, M., Montalvo, W., Al-Shamkhani, A., & Allison, J. P. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019499 · Cited by 213
“Also, CTLA-4 appears to support the function of the regulatory T-cell (Treg) compartment [3].”
BackgroundPenaloza-MacMaster, P., Kamphorst, A. O., Wieland, A., Araki, K., Iyer, S. S., West, E. E., O’Mara, L., Yang, S., Konieczny, B. T., Sharpe, A. H., et al. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20132577 · Cited by 213
“We observed an increase in B7 and PD-L1 expression on DCs after T reg cell depletion.”
BackgroundInfluentialDeletion of CTLA-4 on regulatory T cells during adulthood leads to resistance to autoimmunity
Paterson, A. M., Lovitch, S. B., Sage, P. T., Juneja, V. R., Lee, Y., Trombley, J. D., Arancibia-Cárcamo, C. V., Sobel, R. A., Rudensky, A. Y., Kuchroo, V. K., et al. (2015) · Journal of Experimental Medicine · doi:10.1084/jem.20141030 · Cited by 212
“CTLA-4 has been suggested to down-regulate B7-1 or B7-2 on APCs, either by indirect suppression of the APC, signaling through B7, or removal of B7 from the cell surface by trans-endocytosis (Fallarino et al., 2003; Onishi et al., 2008; Wing et al., 2008; Qureshi et al., 2011).”
BackgroundBai, J.-W., Qiu, S.-Q., & Zhang, G.-J. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01366-y · Cited by 210
“In addition, CTLA-4 is abundantly found in forkhead box p3 (Foxp3) regulatory T cells (Tregs), which mainly works to suppress T-cell activity.(81) Therefore, CTLA4 is considered a negative regulator of T-cell activation.”
BackgroundA novel role of IL-17–producing lymphocytes in mediating lytic bone disease in multiple myeloma
Noonan, K., Marchionni, L., Anderson, J., Pardoll, D., Roodman, G. D., & Borrello, I. (2010) · Blood · doi:10.1182/blood-2010-05-283895 · Cited by 210
Current Perspectives in Cancer Immunotherapy
Christofi, T., Baritaki, S., Falzone, L., Libra, M., & Zaravinos, A. (2019) · Cancers · doi:10.3390/cancers11101472 · Cited by 210
“1/2) CTLA-4 (CD152) [104] PD-L1/2 PD-1 [105] PD-L1 B7-1 (CD80) [106] IDO1/2, TDO Tryptophan [22,107] HVEM (CD270) BTLA, CD160 [108] GAL9, PtdSer, HMGB1, Ceacam-1 TIM3 [109,110] PVR (CD155) CD96, TIGIT, DNAM-1 [111,112] PVRL2 (CD112) CD112R, TIGIT [113,114] Adenosine A2aR [115] CD200 CD200R [116] B7-H3 (CD276) ?, IL20R…”
Control of Regulatory T Cell Migration, Function, and Homeostasis
Campbell, D. J. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1500801 · Cited by 208
“Consistent with this model, loss of CLTA-4 expression in Tregs resulted in lymphoproliferative disease marked by aberrant T cell activation, as well as severe lymphadenopathy and splenomegaly (20).”
BackgroundChen, X., Subleski, J. J., Hamano, R., Howard, O. M. Z., Wiltrout, R. H., & Oppenheim, J. J. (2010) · European Journal of Immunology · doi:10.1002/eji.200940022 · Cited by 207
An obligate cell-intrinsic function for CD28 in Tregs
Zhang, R., Huynh, A., Whitcher, G., Chang, J., Maltzman, J. S., & Turka, L. A. (2013) · Journal of Clinical Investigation · doi:10.1172/jci65013 · Cited by 207
“…confounded by the trans effects of loss of CD28-mediated costimulation and cytokine production by effector T cells or by interruption of CTLA-4 binding to CD80 and CD86, with the resultant loss of CTLA-4 mediated negative signals on effector T cells or CTLA-4–mediated suppression by Tregs (16, 17).”
Ha, D., Tanaka, A., Kibayashi, T., Tanemura, A., Sugiyama, D., Wing, J. B., Lim, E. L., Teng, K. W. W., Adeegbe, D., Newell, E. W., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1812186116 · Cited by 205
“One of various suppression mechanisms used by Treg cells is CTLA-4–dependent down-regulation of CD80 and CD86 expression by dendritic cells (DCs) (14, 15).”
BackgroundSelf-citationDillman, R. O. (2011) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2010.0902 · Cited by 212
“The cells included in this category are CD4þ CD25 CD45ROþ memory helper T-cells.”
BackgroundInfluentialWillsmore, Z. N., Coumbe, B. G. T., Crescioli, S., Reci, S., Gupta, A., Harris, R. J., Chenoweth, A., Chauhan, J., Bax, H. J., McCraw, A., et al. (2021) · European Journal of Immunology · doi:10.1002/eji.202048747 · Cited by 204
Sarcomatoid renal cell carcinoma: biology, natural history and management
Blum, K. A., Gupta, S., Tickoo, S. K., Chan, T. A., Russo, P., Motzer, R. J., Karam, J. A., & Hakimi, A. A. (2020) · Nature Reviews Urology · doi:10.1038/s41585-020-00382-9 · Cited by 203
Pentcheva‐Hoang, T., Corse, E., & Allison, J. P. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00763.x · Cited by 203
“The idea that CTLA-4 might be able to ‘reverse’ signal into APCs via B7-1 is reinforced by experiments showing that CTLA-4-Ig administration extends the long-term cardiac allograft survival in mice, and the success of the treatment depends on the expression of B7-1 by the allograft donor but not by the recipient (105,…”
BackgroundInfluentialPark, H. J., Park, J. S., Jeong, Y. H., Son, J., Ban, Y. H., Lee, B.-H., Chen, L., Chang, J., Chung, D. H., Choi, I., et al. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1401936 · Cited by 201
Expansion of tumor-associated Treg cells upon disruption of a CTLA-4-dependent feedback loop
Marangoni, F., Zhakyp, A., Corsini, M., Geels, S. N., Carrizosa, E., Thelen, M., Mani, V., Prüßmann, J. N., Warner, R. D., Ozga, A. J., et al. (2021) · Cell · doi:10.1016/j.cell.2021.05.027 · Cited by 201
The Use of Immune Checkpoint Inhibitors in Oncology and the Occurrence of AKI: Where Do We Stand?
Franzin, R., Netti, G. S., Spadaccino, F., Porta, C., Gesualdo, L., Stallone, G., Castellano, G., & Ranieri, E. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.574271 · Cited by 201
“(10), during the screening of a mouse T-cell derived cDNA libraries CTLA-4 has been demonstrated to be expressed not only on activated T cells, but also on regulatory T-cells (Tregs), due to their high levels of FoxP3, which is known to regulate CTLA-4 expression (11).”
BackgroundJeffery, L. E., Wood, A. M., Qureshi, O. S., Hou, T. Z., Gardner, D., Briggs, Z., Kaur, S., Raza, K., & Sansom, D. M. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1200786 · Cited by 201
Detection of self-reactive CD8 + T cells with an anergic phenotype in healthy individuals
Maeda, Y., Nishikawa, H., Sugiyama, D., Ha, D., Hamaguchi, M., Saito, T., Nishioka, M., Wing, J. B., Adeegbe, D., Katayama, I., et al. (2014) · Science · doi:10.1126/science.aaa1292 · Cited by 200
Self-citationFransen, M. F., van der Sluis, T. C., Ossendorp, F., Arens, R., & Melief, C. J. M. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0781 · Cited by 200
“molecules on APCs and induction of APC-expressed IDO, a metabolic enzyme that catabolizes tryptophan leading to starvation of T cells (10, 11).”
BackgroundWang, J., Perry, C. J., Meeth, K., Thakral, D., Damsky, W., Micevic, G., Kaech, S., Blenman, K., & Bosenberg, M. (2017) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12591 · Cited by 199
“CTLA-4 has been shown to be constitutively expressed on regulatory T cells and critical for their function (61, 62).”
BackgroundRegulatory T Cells: Regulation of Identity and Function
Grover, P., Goel, P. N., & Greene, M. I. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.750542 · Cited by 199
Much Ado about Adenosine: Adenosine Synthesis and Function in Regulatory T Cell Biology
Ernst, P. B., Garrison, J. C., & Thompson, L. F. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1000108 · Cited by 199
“Furthermore, inhibition of host responses mediated by interactions of LAG3 (48) and CTLA-4 (41) on Tregs with their respective receptors on target cells requires intimate contact (40).”
BackgroundShenghui, Z., Yixiang, H., Jianbo, W., Kang, Y., Laixi, B., Yan, Z., & Xi, X. (2011) · International Journal of Cancer · doi:10.1002/ijc.25791 · Cited by 199
“Several studies have shown that blocking of these receptors or inhibiting cytokines production on Treg can decrease the suppressor function, enhance anti-tumor immunity and induce tumor recession.(28,32,33) These results suggest that the dif-”
BackgroundT cell exhaustion: from pathophysiological basics to tumor immunotherapy
Catakovic, K., Klieser, E., Neureiter, D., & Geisberger, R. (2017) · Cell Communication and Signaling · doi:10.1186/s12964-016-0160-z · Cited by 199
“Additionally, CTLA-4 expressing Tregs mediate the downregulation of CD80/ CD86 on antigen presenting cells and thereby reduce activation of naïve T cells [40, 41].”
BackgroundCD226 opposes TIGIT to disrupt Tregs in melanoma
Fourcade, J., Sun, Z., Chauvin, J.-M., Ka, M., Davar, D., Pagliano, O., Wang, H., Saada, S., Menna, C., Amin, R., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.121157 · Cited by 199
MIF-Dependent Control of Tumor Immunity
Noe, J. T., & Mitchell, R. A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.609948 · Cited by 198
Human regulatory T cells induce T-lymphocyte senescence
Ye, J., Huang, X., Hsueh, E. C., Zhang, Q., Ma, C., Zhang, Y., Varvares, M. A., Hoft, D. F., & Peng, G. (2012) · Blood · doi:10.1182/blood-2012-03-416040 · Cited by 198
Adaptive immunity in atherogenesis: new insights and therapeutic approaches
Lichtman, A. H., Binder, C. J., Tsimikas, S., & Witztum, J. L. (2013) · Journal of Clinical Investigation · doi:10.1172/jci63108 · Cited by 198
“108, 109, and see Figure 2), and secretion of the suppressive cytokines IL-10, IL-35, IL-9, and TGF-β (110).”
Costimulatory pathways in transplantation: challenges and new developments
Li, X. C., Rothstein, D. M., & Sayegh, M. H. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00781.x · Cited by 197
“CTLA-4 also plays a key role in the activity of Foxp3 Treg and probably in the responsiveness of T-effector cells to suppression (145).”
BackgroundImmunotherapy for hepatocellular carcinoma: Current and future
Johnston, M. P., & Khakoo, S. I. (2019) · World Journal of Gastroenterology · doi:10.3748/wjg.v25.i24.2977 · Cited by 197
Molecular Mechanisms of T Cells Activation by Dendritic Cells in Autoimmune Diseases
Tai, Y., Wang, Q., Korner, H., Zhang, L., & Wei, W. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00642 · Cited by 196
Cell Surface Signaling Molecules in the Control of Immune Responses: A Tide Model
Zhu, Y., Yao, S., & Chen, L. (2011) · Immunity · doi:10.1016/j.immuni.2011.04.008 · Cited by 196
IRF4 instructs effector Treg differentiation and immune suppression in human cancer
Alvisi, G., Brummelman, J., Puccio, S., Mazza, E. M. C., Tomada, E. P., Losurdo, A., Zanon, V., Peano, C., Colombo, F. S., Scarpa, A., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci130426 · Cited by 195
“The main role of Tregs is to maintain immune homeostasis in physiology by inhibiting effector T cells via different modes of action, including expression of cell-surface inhibitors, such as cytotoxic T lymphocyte–associated protein 4 (CTLA-4) (3); production of inhibitory cytokines, such as IL-10 (4), TGF-β (5), or IL…”
BackgroundInfluentialImmunomodulatory Activity of VEGF in Cancer
(2017) · International Review of Cell and Molecular Biology · doi:10.1016/bs.ircmb.2016.09.007 · Cited by 194
T regulatory cells: hypoxia-adenosinergic suppression and re-direction of the immune response
Sitkovsky, M. V. (2009) · Trends in Immunology · doi:10.1016/j.it.2008.12.002 · Cited by 193
Erratum: The future of cancer treatment: immunomodulation, CARs and combination immunotherapy
Khalil, D. N., Smith, E. L., Brentjens, R. J., & Wolchok, J. D. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.65 · Cited by 191
Exploiting CTLA-4, PD-1 and PD-L1 to reactivate the host immune response against cancer
Quezada, S. A., & Peggs, K. S. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.117 · Cited by 190
“In addition, its engagement with B7 ligands appears to deliver inhibitory signals into the ligand-expressing cells, and it also has suppressive activity in trans when expressed on either regulatory or effector T cells (Wing et al, 2008; Corse and Allison, 2012).”
BackgroundRegulatory T Cells: Barriers of Immune Infiltration Into the Tumor Microenvironment
Scott, E. N., Gocher, A. M., Workman, C. J., & Vignali, D. A. A. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.702726 · Cited by 190
“Interestingly, Treg ligation of CD80/CD86 on dendritic cells (DCs) via CTLA-4, increases the production of IDO (47) (Figure 1A).”
BackgroundVocanson, M., Rozieres, A., Hennino, A., Poyet, G., Gaillard, V., Renaudineau, S., Achachi, A., Benetiere, J., Kaiserlian, D., Dubois, B., et al. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2010.05.022 · Cited by 189
Role of the immunosuppressive microenvironment in immunotherapy
Tormoen, G. W., Crittenden, M. R., & Gough, M. J. (2018) · Advances in Radiation Oncology · doi:10.1016/j.adro.2018.08.018 · Cited by 189
Modulation of regulatory T cell function and stability by co-inhibitory receptors
Lucca, L. E., & Dominguez-Villar, M. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0296-3 · Cited by 189
CTLA4 blockade increases Th17 cells in patients with metastatic melanoma
von Euw, E., Chodon, T., Attar, N., Jalil, J., Koya, R. C., Comin-Anduix, B., & Ribas, A. (2009) · Journal of Translational Medicine · doi:10.1186/1479-5876-7-35 · Cited by 189
“The interest is based on several lines of evidence, including the overlapping phenotype of autoimmune conditions in CTLA4 and FoxP3 deficient mice, and evidence that Treg-specific deficiency in CTLA4 expression impairs the suppressive function of Tregs [25].”
Takahashi, R., Nishimoto, S., Muto, G., Sekiya, T., Tamiya, T., Kimura, A., Morita, R., Asakawa, M., Chinen, T., & Yoshimura, A. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20110428 · Cited by 188
“…other phenotypical markers of Treg cells, CD25 and CTLA4, which have been shown to be critical molecules in the suppression activity of Treg cells (Wing et al., 2008), were altered in transferred SOCS1deficient (C) Representative macroscopic view of the spleen and LN of a Socs1f/f (WT) mouse and…”
BackgroundHuang, N., Chi, H., & Qiao, J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01023 · Cited by 191
“Furthermore, specific deficiency of CTLA4 in Tregs results in the spontaneous development of systemic lymphoproliferation, multi-organ lymphocyte infiltrations, fatal T cell-mediated autoimmune diseases, and hyperproduction of immunoglobulin E in mice (43).”
BackgroundSuppressing T cell motility induced by anti–CTLA-4 monotherapy improves antitumor effects
Ruocco, M. G., Pilones, K. A., Kawashima, N., Cammer, M., Huang, J., Babb, J. S., Liu, M., Formenti, S. C., Dustin, M. L., & Demaria, S. (2012) · Journal of Clinical Investigation · doi:10.1172/jci61931 · Cited by 187
“Non-autonomous effects of CTLA-4 include the reduction of CD80 and CD86 from the surface of dentritic cells by regulatory and effector T cell–mediated trogocytosis (11, 12).”
CTLA-4, an Essential Immune-Checkpoint for T-Cell Activation
Chikuma, S. (2017) · Current topics in microbiology and immunology · doi:10.1007/82_2017_61 · Cited by 191
Non–Small-Cell Lung Cancer: Role of the Immune System and Potential for Immunotherapy
Carbone, D. P., Gandara, D. R., Antonia, S. J., Zielinski, C., & Paz-Ares, L. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000551 · Cited by 186
“CTLA-4 is also constitutively expressed by T reg cells and has a critical effect on the ability of these cells to regulate antitumor immunity.(22) The PD-1 pathway is also an important mechanism by which tumors develop immune resistance (Fig.”
BackgroundHsu, P., Santner-Nanan, B., Dahlstrom, J. E., Fadia, M., Chandra, A., Peek, M., & Nanan, R. (2012) · The American Journal of Pathology · doi:10.1016/j.ajpath.2012.08.032 · Cited by 186
Metadata
- Authors
- Wing, K., Onishi, Y., Prieto-Martin, P., Yamaguchi, T., Miyara, M., Fehervari, Z., Nomura, T., & Sakaguchi, S.
- Affiliations
- Tohoku University (JP)
- Department of Experimental Pathology, Institute for Frontier Medical Sciences, Kyoto University, Kyoto 606-8507, Japan.
- Corresponding author
- Wing, Kajsa
- Sakaguchi, Shimon
- Venue
- Science
- Published
- 2008-10-10
- Volume
- 322
- Issue
- 5899
- Pages
- 271-275
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2061071534
- Cited by
- 2,956
- References
- 25
- Citations by year
- 2026: 122 · 2025: 129 · 2024: 154 · 2023: 142 · 2022: 162 · 2021: 198 · 2020: 186 · 2019: 205 · 2018: 197 · 2017: 187 · 2016: 174 · 2015: 162 · 2014: 158 · 2013: 170 · 2012: 167
- FWCI
- 61.33
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- CTLA-4, Foxp3+ regulatory T cells, Treg suppressive function, lymphoproliferation, autoimmune disease, immunoglobulin E, antitumor immunity, dendritic cells, CD80, CD86, antigen presentation, immune tolerance
- MeSH terms
- Animals, Antigen-Presenting Cells, Autoimmune Diseases, Dendritic Cells, Female, Immunoglobulin E, Immunoglobulin G, Immune Tolerance, Leukemia, Lymphocyte Activation, Lymphocytes, Male, Mice, Inbred BALB C, Down-Regulation, Autoimmunity, Antigens, CD, B7-1 Antigen, CD8-Positive T-Lymphocytes, T-Lymphocytes, Regulatory, Mice, Forkhead Transcription Factors, B7-2 Antigen, CTLA-4 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.